Ponatinib Receives Marketing Authorization in Europe for CML and Ph+ ALL
ARIAD has received marketing authorization from the European Commission for ponatinib (Iclusig) in chronic myeloid leukemia and acute lymphoblastic leukemia.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Marketing